N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

McCallum, Matthew, De Marco, Anna, Lempp, Florian A., Tortorici, M. Alejandra, Pinto, Dora, Walls, Alexandra C., Beltramello, Martina, Chen, Alex +26 more·2021·Cell
DOI 10.1016/j.cell.2021.03.028

Cited by (909)

Items 201–300 of 909

  1. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people
    Tara M. Narowski, Kristin Raphel, Lily E. Adams, Jenny Huang, Nadja A. Vielot, Ramesh Jadi, Aravinda M. de Silva, Ralph Steven Baric, John Lafleur, Lakshmanane Premkumar · 2022 · Cell Reports
  2. Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection With accumulation of mutations in a patient with poorly controlled Human Immunodeficiency Virus infection
    Tongai Gibson Maponga, Montenique Jeffries, Houriiyah Tegally, Andrew D. Sutherland, Eduan Wilkinson, Richard J. Lessells, Nokukhanya Msomi, Gert Uves van Zyl, Túlio de Oliveira, Wolfgang Preiser · 2022 · Clinical Infectious Diseases
  3. Inter-domain communication in SARS-CoV-2 spike proteins controls protease-triggered cell entry
    Enya Qing, Pengfei Li, Laura M. Cooper, Sebastian R. Schulz, Hans‐Martin Jäck, Lijun Rong, Stanley M. Perlman, Tom Gallagher · 2022 · Cell Reports
  4. Rapid characterization of spike variants via mammalian cell surface display
    Kamyab Javanmardi, Chia‐Wei Chou, Cynthia I. Terrace, Ankur Annapareddy, Tamer Saad Kaoud, Qingqing Guo, Josh Lutgens, Hayley Zorkic, Andrew P. Horton, Elizabeth C. Gardner et al. · 2021 · Molecular Cell
  5. Protective neutralizing epitopes in SARS‐CoV‐2
    Hejun Liu, Ian A. Wilson · 2022 · Immunological Reviews
  6. Antigen- and scaffold-specific antibody responses to protein nanoparticle immunogens
    John C. Kraft, Minh Nguyet Pham, Laila Shehata, Mitch Brinkkemper, Seyhan Boyoglu-Barnum, Kaitlin R. Sprouse, Alexandra C. Walls, Suna Cheng, Mike Murphy, Deleah Pettie et al. · 2022 · Cell Reports Medicine
  7. Diagnostics and analysis of SARS-CoV-2: current status, recent advances, challenges and perspectives
    Tao Dong, Mingyang Wang, Junchong Liu, Pengxin Ma, Shuang Pang, Wanjian Liu, Aihua Liu · 2023 · Chemical Science
  8. SARS-CoV-2 spike protein: structure, viral entry and variants
    Bing Chen, Michael Farzan, Hyeryun Choe · 2025 · Nature Reviews Microbiology
  9. Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis
    Frauke Muecksch, H. Wise, K. Templeton, Becky Batchelor, M. Squires, Kirsty McCance, L. Jarvis, K. Malloy, E. Furrie, C. Richardson et al. · 2022 · The Lancet Microbe
  10. Rapid lateral flow tests for the detection of SARS-CoV-2 neutralizing antibodies
    Jianfu J. Wang, Nan Zhang, Sarah A. Richardson, Jin V. Wu · 2021 · Expert Review of Molecular Diagnostics
  11. SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies
    Prerna Arora, Lu Zhang, Nadine Krüger, Cheila Rocha, Anzhalika Sidarovich, Sebastian R. Schulz, Amy Madeleine Kempf, Luise Graichen, Anna-Sophie Moldenhauer, Anne Cossmann et al. · 2022 · Cell Host & Microbe
  12. Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance
    Lirong Cao, Jingzhi Lou, See Yeung Chan, Hong Zheng, Caiqi Liu, Shi Zhao, Qi Li, Chris Ka Pun Mok, Renee W. Y. Chan, Ka Chun Chong et al. · 2022 · Nature Medicine
  13. Variations within the Glycan Shield of SARS-CoV-2 Impact Viral Spike Dynamics
    M. Newby, C. Fogarty, J. Allen, J. Butler, E. Fadda, M. Crispin · 2022 · Journal of Molecular Biology
  14. Human coronavirus HKU1 recognition of the TMPRSS2 host receptor
    Matthew McCallum, Young‐Jun Park, Cameron Stewart, Kaitlin R. Sprouse, Amin Addetia, Jack T Brown, M. Alejandra Tortorici, Cecily A. Gibson, Emily Wong, Margareta M. Ieven et al. · 2024 · Cell
  15. COVID-19, the first pandemic in the post-genomic era
    Lucy van Dorp, Charlotte J. Houldcroft, Damien Richard, François Balloux · 2021 · Current Opinion in Virology
  16. Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities
    Yaozong Chen, Lulu Sun, Irfan Ullah, Guillaume Beaudoin-Bussières, Sai Priya Anand, Andrew P. Hederman, William David Tolbert, Rebekah T. Sherburn, Dung Ngoc Pham Nguyen, Lorie Marchitto et al. · 2022 · Science Advances
  17. A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron
    Ryota Maeda, Junso Fujita, Yoshinobu Konishi, Yasuhiro Kazuma, Hiroyuki Yamazaki, Itsuki Anzai, Tokiko Watanabe, Keishi Yamaguchi, Kazuki Kasai, Kayoko Nagata et al. · 2022 · Communications Biology
  18. Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron
    I‐Ting Teng, Alexandra F. Nazzari, Misook Choe, Tracy W. B. Liu, Matheus Oliveira de Souza, Yuliya I. Petrova, Yaroslav Tsybovsky, Shuishu Wang, Baoshan Zhang, Mykhaylo V Artamonov et al. · 2022 · PLoS ONE
  19. Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron
    Lidong Wang, Michelle Møhlenberg, Pengfei Wang, Hao Zhou · 2023 · Cytokine & Growth Factor Reviews
  20. Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs
    Jesús Horacio Lara Puente, Juan Manuel Carreño, Weina Sun, Alejandro Suárez-Martínez, Luis Alfonso Ramírez-Martínez, Francisco Quezada-Monroy, Georgina Paz-De la Rosa, Rosalía Vigueras-Moreno, Gagandeep Singh, Oscar Rojas-Martínez et al. · 2021 · mBio
  21. The Genetic Variant of SARS-CoV-2: Would it matter for Controlling the Devastating Pandemic?
    Shuxin Guo, Kefang Liu, Jun Zheng · 2021 · International Journal of Biological Sciences
  22. A neutralizing epitope on the SD1 domain of SARS-CoV-2 spike targeted following infection and vaccination
    J. Seow, Hataf Khan, Annachiara Rosa, Valeria Calvaresi, C. Graham, S. Pickering, V. E. Pye, N. Cronin, I. Huettner, M. Malim et al. · 2022 · Cell Reports
  23. Molecular insights into the adaptive evolution of SARS-CoV-2 spike protein
    Zhuocheng Yao, Lin Zhang, Yuange Duan, Xiaolu Tang, Jian Lü · 2024 · Journal of Infection
  24. Molecular basis of convergent evolution of ACE2 receptor utilization among HKU5 coronaviruses
    Young‐Jun Park, Chen Liu, Jimin Lee, Jack T Brown, Chengbao Ma, Peng Liu, Risako Gen, Qing Xiong, Samantha K. Zepeda, Cameron Stewart et al. · 2025 · Cell
  25. Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview
    Rukmankesh Mehra, Kasper P. Kepp · 2021 · ACS Infectious Diseases
  26. The Development of SARS-CoV-2 Variants: The Gene Makes the Disease
    Raquel Pérez-Gómez · 2021 · Journal of Developmental Biology
  27. Multiple expansions of globally uncommon SARS-CoV-2 lineages in Nigeria
    Egon A. Ozer, Lacy M. Simons, O. M. Adewumi, A. Fowotade, E. Omoruyi, J. Adeniji, O. A. Olayinka, Taylor J Dean, Janet P Zayas, Pavan P. Bhimalli et al. · 2022 · Nature Communications
  28. Profiles of current COVID-19 vaccines
    Franz Xaver Heinz, Karin Stiasny · 2021 · Wiener klinische Wochenschrift
  29. The ongoing evolution of variants of concern and interest of SARS-CoV-2 in Brazil revealed by convergent indels in the amino (N)-terminal domain of the spike protein
    Paola Cristina Resende, Felipe Gomes Naveca, Roberto Dias Lins, Filipe Zimmer Dezordi, Matheus Vitor Ferreira Ferraz, Emerson Gonçalves Moreira, Danilo F. Coêlho, Fernando Couto Motta, Anna Carolina Dias Paixão, Luciana Appolinario et al. · 2021 · Virus Evolution
  30. Emergence of a recurrent insertion in the N-terminal domain of the SARS-CoV-2 spike glycoprotein
    Marco Gerdol, Klevia Dishnica, Alejandro Giorgetti · 2022 · Virus Research
  31. Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models
    Martín A. Rossotti, Henk van Faassen, Anh Tran, Joey G. Sheff, Jagdeep K. Sandhu, Diana Duque, Melissa Hewitt, Xiaoxue Wen, Jegarubee Bavananthasivam, Saina Beitari et al. · 2022 · Communications Biology
  32. SARS-CoV-2 journey: from alpha variant to omicron and its sub-variants
    Dima Hattab, Mumen F. A. Amer, Zina M. Al‐Alami, Athirah Bakhtiar · 2024 · Infection
  33. Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination
    Jordan J. Clark, Irene Hoxie, Daniel C. Adelsberg, Iden A. Sapse, Robert Andreata‐Santos, Jeremy S. Yong, Fatima Amanat, Johnstone Tcheou, Ariel J. Raskin, Gagandeep Singh et al. · 2024 · Cell Reports
  34. Evolution of the SARS-CoV-2 genome and emergence of variants of concern
    Iman Safari, Elahe Elahi · 2021 · Archives of Virology
  35. Discovery of adapalene and dihydrotachysterol as antiviral agents for the Omicron variant of SARS-CoV-2 through computational drug repurposing
    Özkan Fidan, Somdutt Mujwar, Mateusz Kciuk · 2022 · Molecular Diversity
  36. SARS-CoV-2 Spike Protein Mutations and Escape from Antibodies: A Computational Model of Epitope Loss in Variants of Concern
    Alice Triveri, Stefano Artin Serapian, Filippo Marchetti, Filippo Doria, Silvia Pavoni, Fabrizio Cinquini, Elisabetta Moroni, Andrea Rasola, Francesco Frigerio, Giorgio Colombo · 2021 · Journal of Chemical Information and Modeling
  37. Electron microscopy holdings of the Protein Data Bank: the impact of the resolution revolution, new validation tools, and implications for the future
    Stephen Kevin Burley, Helen Miriam Berman, Wah Chiu, Wei Dai, Justin W. Flatt, Brian P. Hudson, Jason T. Kaelber, Sagar D. Khare, Arek Kulczyk, Catherine L. Lawson et al. · 2022 · Biophysical Reviews
  38. Detection of R.1 lineage severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with spike protein W152L/E484K/G769V mutations in Japan
    Yosuke Hirotsu, Masao Omata · 2021 · PLoS Pathogens
  39. A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses
    Klara Lenart, Fredrika Hellgren, Sebastian Ols, Xianglei Yan, Alberto Cagigi, Rodrigo Arcoverde Cerveira, Inga Patrycja Winge, Jakub Hanczak, Stefan O. Mueller, Edith Jasny et al. · 2022 · Molecular Therapy — Methods & Clinical Development
  40. High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spike
    Timothy J.C. Tan, Zongjun Mou, Ruipeng Lei, Wenhao O. Ouyang, Meng Yuan, Ge Song, Raiees Andrabi, Ian A. Wilson, Collin Kieffer, Xinghong Dai et al. · 2023 · Nature Communications
  41. The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies and targets both the NTD and the RBD
    Fatima Amanat, Mahima Thapa, Tinting Lei, Shaza M. Sayed Ahmed, Daniel C. Adelsberg, Juan Manuel Carreño, Shirin Strohmeier, Aaron J. Schmitz, Sarah Zafar, Julian Q. Zhou et al. · 2021 · medRxiv
  42. A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2
    Kang Wang, Yunlong Cao, Yunjiao Zhou, Jiajing Wu, Zijing Jia, Yaling Hu, Ayijiang Yisimayi, Wangjun Fu, Lei Wang, Pan Liu et al. · 2021 · medRxiv
  43. The rapid adaptation of SARS-CoV-2–rise of the variants: transmission and resistance
    Sandrine Mabekou Soh, Yeongjun Kim, Chanwoo Kim, Ui Soon Jang, Hye-Ra Lee · 2021 · The Journal of Microbiology
  44. The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum
    Lu Lu, Allen Wing‐Ho Chu, Ruiqi Zhang, Wan-Mui Chan, Jonathan Daniel Ip, Hoi‐Wah Tsoi, Lin‐Lei Chen, Jian‐Piao Cai, David Christopher Lung, Anthony Raymond Tam et al. · 2021 · EBioMedicine
  45. SARS-CoV-2 Virus−Host Interaction: Currently Available Structures and Implications of Variant Emergence on Infectivity and Immune Response
    Luís Queirós-Reis, Priscilla Gomes da Silva, José Gonçalves, Andrea Brancale, Marcella Bassetto, João R. Mesquita · 2021 · International Journal of Molecular Sciences
  46. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity
    Jitendra Kumar Chaudhary, Rohitash Yadav, Pankaj Kumar Chaudhary, Anurag Maurya, Nimita Kant, Osamah Al Rugaie, Hoineiting Rebecca Haokip, Deepika Yadav, Rakesh Roshan, Ramasare Prasad et al. · 2021 · Cells
  47. A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants
    Zhen-Lin Yang, Yulu Wang, Yu-jia Jin, Yuan-Fei Zhu, Yan-Ling Wu, Cheng Li, Yu Kong, Wen-Ping Song, Xiaolong Tian, Wuqiang Zhan et al. · 2021 · Signal Transduction and Targeted Therapy
  48. Within-host genetic diversity of SARS-CoV-2 lineages in unvaccinated and vaccinated individuals
    Haogao Gu, Ahmed Abdul Quadeer, Pavithra Krishnan, Daisy Y.M. Ng, Lydia D.J. Chang, Gigi Y.Z. Liu, Samuel M. S. Cheng, Tommy Tsan‐Yuk Lam, Malik J. S. Peiris, Matthew R. McKay et al. · 2023 · Nature Communications
  49. SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1
    John Lokman Law, Michael R Logan, Michael Joyce, Abdolamir Landi, Darren J. Hockman, Kevin Crawford, Janelle Johnson, Gerald LaChance, Holly A. Saffran, Justin A. Shields et al. · 2021 · Vaccine
  50. SARS-CoV-2 spike E156G/Δ157-158 mutations contribute to increased infectivity and immune escape
    Tarun Kumar Mishra, Rishikesh Dalavi, Garima Joshi, Atul Kumar, Pankaj Pandey, Sanjeev Shukla, Ram Kumar Mishra, Ajit G. Chande · 2022 · Life Science Alliance
  51. Allosteric perspective on the mutability and druggability of the SARS-CoV-2 Spike protein
    Zhen Wah Tan, Wei-Ven Tee, Firdaus Samsudin, Enrico Guarnera, Peter John Bond, Igor N. Berezovsky · 2022 · Structure
  52. Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein
    Kamyab Javanmardi, Thomas H. Segall-Shapiro, Chia‐Wei Chou, Daniel R. Boutz, Randall J. Olsen, Xuping Xie, Hongjie Xia, Pei‐Yong Shi, Charlie D. Johnson, Ankur Annapareddy et al. · 2022 · Cell Host & Microbe
  53. The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency
    Prerna Arora, Cheila Rocha, Amy Madeleine Kempf, Inga Nehlmeier, Luise Graichen, Martin Sebastian Winkler, Martin Lier, Sebastian R. Schulz, Hans‐Martin Jäck, Anne Cossmann et al. · 2021 · Cellular and Molecular Immunology
  54. Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
    William R. Strohl, Zhiqiang Ku, Zhiqiang An, Stephen F. Carroll, Bruce A. Keyt, Lila M. Strohl · 2022 · BioDrugs
  55. TEMPO: A transformer-based mutation prediction framework for SARS-CoV-2 evolution
    Binbin Zhou, Hang Zhou, Xue Zhang, Xiaobin Xu, Yi Chai, Zengwei Zheng, Alex Chichung Kot, Zhan Mei Zhou · 2022 · Computers in Biology and Medicine
  56. Should we discount the laboratory origin of COVID-19?
    Rossana Segreto, Yuri Deigin, Kevin McCairn, Alejandro Sousa, Dan Sirotkin, Karl M. Sirotkin, Jonathan J. Couey, Adrian Jones, Daoyu Zhang · 2021 · Environmental Chemistry Letters
  57. CRISPR techniques and potential for the detection and discrimination of SARS-CoV-2 variants of concern
    Huyan Xiao, Jianyu Hu, Camille Huang, Wei Feng, Yanming Liu, Teresa Kumblathan, Jeffrey Tao, Jingyang Xu, X. Chris Le, Hongquan Zhang · 2023 · TrAC Trends in Analytical Chemistry
  58. The localized rise of a B.1.526 SARS-CoV-2 variant containing an E484K mutation in New York State
    Erica Lasek‐Nesselquist, Pascal Lapierre, Erasmus Schneider, Kirsten St. George, Janice D. Pata · 2021 · medRxiv
  59. Coincident rapid expansion of two SARS-CoV-2 lineages with enhanced infectivity in Nigeria
    Ozer, Egon A., Simons, Lacy M., Adewumi, Olubusuyi M., Fowotade, Adeola A., Omoruyi, Ewean C., Adeniji, Johnson A., Dean, Taylor J., Zayas, Janet, Bhimalli, Pavan P., Ash, Michelle K. et al. · 2021
  60. Regional and temporal coordinated mutation patterns in SARS-CoV-2 spike protein revealed by a clustering and network analysis
    Surendra S. Negi, Catherine H. Schein, Werner A. Braun · 2022 · Scientific Reports
  61. SARS-CoV-2–specific memory B cells can persist in the elderly who have lost detectable neutralizing antibodies
    Anna Jeffery-Smith, Alice R. Burton, Sabela Lens, Chloe Rees-Spear, Jessica E. Davies, Monika Patel, Robin Gopal, Luke Muir, Felicity Aiano, Katie J. Doores et al. · 2021 · Journal of Clinical Investigation
  62. Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies
    Qingrui Huang, Xiaonan Han, Jinghua Yan · 2022 · Emerging Microbes & Infections
  63. SARS-CoV-2 spike protein as a bacterial lipopolysaccharide delivery system in an overzealous inflammatory cascade
    Firdaus Samsudin, Palur Venkata Raghuvamsi, Ganna Petruk, Manoj Puthia, Jitka Petrlová, Paul A. MacAry, Ganesh S. Anand, Peter John Bond, Artur Schmidtchen · 2022 · Journal of Molecular Cell Biology
  64. Molecular Evolution of SARS-CoV-2 during the COVID-19 Pandemic
    Luis Daniel González-Vázquez, Miguel Arenas · 2023 · Genes
  65. Antigenic evolution of SARS coronavirus 2
    Anna Z. Mykytyn, Ron A. M. Fouchier, Bart L. Haagmans · 2023 · Current Opinion in Virology
  66. SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response
    Davide Mileto, Claudio Fenizia, Miriam Cutrera, G. Gagliardi, Anna Gigantiello, Annalisa De Silvestri, Alberto Rizzo, Alessandro Mancon, Martina Bianchi, Fernando Poli et al. · 2021 · Emerging Microbes & Infections
  67. Glycosylation in SARS-CoV-2 variants: A path to infection and recovery
    Arya Aloor, Rajaguru Aradhya, Parvathy Venugopal, Bipin Gopalakrishnan Nair, Renuka Suravajhala · 2022 · Biochemical Pharmacology
  68. Initial immune response after exposure to Mycobacterium tuberculosis or to SARS-COV-2: similarities and differences
    Alessandra Aiello, Saeid Najafi Fard, Delia Goletti · 2023 · Frontiers in Immunology
  69. Performance evaluation of four surrogate Virus Neutralization Tests (sVNTs) in comparison to the in vivo gold standard test
    Massimo Pieri, Maria Giaele Infantino, Mariangela Manfredi, Marzia Nuccetelli, Valentina Grossi, Barbara Lari, Flaminia Tomassetti, Serena Sarubbi, Edda Russo, Amedeo Amedei et al. · 2022 · Frontiers in Bioscience-Landmark
  70. Thermodynamically coupled biosensors for detecting neutralizing antibodies against SARS-CoV-2 variants
    Jason Z. Zhang, Andy Hsien-Wei Yeh, Alexandra C. Walls, Basile I. M. Wicky, Kaitlin R. Sprouse, Laura A. VanBlargan, Rebecca S. Treger, Alfredo Quijano‐Rubio, Minh Nguyet Pham, John C. Kraft et al. · 2022 · Nature Biotechnology
  71. Characterization of the SARS-CoV-2 B.1.621 (Mu) variant
    Peter Halfmann, Makoto Kuroda, Tammy Armbrust, James P. Theiler, Ariane Balaram, Gage K. Moreno, Molly A. Accola, Kiyoko Iwatsuki‐Horimoto, Riccardo Valdez, Emily K. Stoneman et al. · 2022 · Science Translational Medicine
  72. Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability
    Wei Shi, Lingshu Wang, Tongqing Zhou, Mallika Sastry, Eun Sung Yang, Yi Zhang, Man Chen, Xuejun Chen, Misook Choe, Adrian Creanga et al. · 2022 · Structure
  73. Evolutionary remodelling of N‐terminal domain loops fine‐tunes SARS‐CoV‐2 spike
    Diego M. Cantoni, Matthew J Murray, Mphatso D. Kalemera, Samuel J. Dicken, Lenka Stejskal, Georgina Brown, Spyros Lytras, Jonathon D. Coey, James Patrick McKenna, Stephen Bridgett et al. · 2022 · EMBO Reports
  74. The emergence and ongoing convergent evolution of the N501Y lineages coincides with a major global shift in the SARS-CoV-2 selective landscape
    Darren P Martin, Steven Weaver, Houryiah Tegally, Emmanuel James San, Stephen D. Shank, Eduan Wilkinson, Alexander G. Lucaci, Jennifer Giandhari, Sureshnee Naidoo, Yeshnee Pillay et al. · 2021 · PubMed
  75. Adaptive Evolution of the Spike Protein in Coronaviruses
    Xiaolu Tang, Zhaohui Qian, Xuemei Lu, Jian Lü · 2023 · Molecular Biology and Evolution
  76. Rapid colloidal gold immunochromatographic assay for the detection of SARS-CoV-2 total antibodies after vaccination
    Liya Ye, Xinxin Xu, Shanshan Song, Liguang Xu, Hua Kuang, Chuanlai Xu · 2022 · Journal of Materials Chemistry B
  77. Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S
    Dominique J. Barbeau, Judith M. Martin, Emily Carney, Emily Dougherty, Joshua Doyle, Terence S. Dermody, Alejandro Hoberman, John V. Williams, Marian G. Michaels, John F. Alcorn et al. · 2022 · npj Vaccines
  78. Characterisation of B.1.1.7 and Pangolin coronavirus spike provides insights on the evolutionary trajectory of SARS-CoV-2
    Samuel J. Dicken, Matthew J Murray, Lucy Thorne, Ann‐Kathrin Reuschl, Calum Forrest, Maaroothen Ganeshalingham, Luke Muir, Mphatso D. Kalemera, Machaela Palor, Laura E. McCoy et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  79. SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity
    Sabari Nath Neerukonda, Russell A. Vassell, Sabrina Lusvarghi, Richard Wang, Fernando Echegaray, Lisa Bentley, Ann E. Eakin, Karl J. Erlandson, Leah C. Katzelnick, Carol D. Weiss et al. · 2021 · Viruses
  80. Broad receptor tropism and immunogenicity of a clade 3 sarbecovirus
    Jimin Lee, Samantha K. Zepeda, Young‐Jun Park, Ashley L. Taylor, Joel D. Quispe, Cameron Stewart, Elizabeth M. Leaf, Catherine Treichel, Davide Corti, Neil P. King et al. · 2023 · Cell Host & Microbe
  81. An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer
    Naveenchandra Suryadevara, Andrea R. Shiakolas, Laura A. VanBlargan, E. Binshtein, Rita E. Chen, J. Case, Kevin J. Kramer, Erica C. Armstrong, Luke Myers, Andrew Trivette et al. · 2022 · bioRxiv
  82. Omicron: a drug developer’s perspective
    Fang Fang, Pei‐Yong Shi · 2021 · Emerging Microbes & Infections
  83. Structural and functional insights into the evolution of SARS-CoV-2 KP.3.1.1 spike protein
    Ziqi Feng, Jiachen Huang, Sabyasachi Baboo, Jolene K. Diedrich, Sandhya Bangaru, James C. Paulson, John R. Yates, Meng Yuan, Ian A. Wilson, Andrew B. Ward · 2025 · Cell Reports
  84. The Immune Response to SARS-CoV-2 and Variants of Concern
    Elham Torbati, Kurt L. Krause, James E. Ussher · 2021 · Viruses
  85. Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern
    A. Gorchakov, S. Kulemzin, S. Guselnikov, K. Baranov, T. N. Belovezhets, L. Mechetina, O. Volkova, A. Najakshin, N. Chikaev, A. Chikaev et al. · 2021 · Cell Discovery
  86. Comparative Genomics and Characterization of SARS-CoV-2 P.1 (Gamma) Variant of Concern From Amazonas, Brazil
    Ricardo Ariel Zimerman, Patrícia Aline Gröhs Ferrareze, Flavio Cadegiani, Carlos Gustavo Wambier, Daniel do Nascimento Fonseca, Andrea Roberto de Souza, Andy Goren, Liane Nanci Rotta, Zhihua Ren, Claudia Elizabeth Thompson · 2022 · Frontiers in Medicine
  87. Inferring effects of mutations on SARS-CoV-2 transmission from genomic surveillance data
    Brian Lee, Ahmed Abdul Quadeer, Muhammad Saqib Sohail, Elizabeth Finney, Syed Faraz Ahmed, Matthew R. McKay, John P. Barton · 2025 · Nature Communications
  88. Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking
    Lihong Liu, Ryan G. Casner, Yicheng Guo, Qian Wang, Sho Iketani, Jasper Fuk‐Woo Chan, Jian Yu, Bernadeta Dadonaite, Manoj S. Nair, Hiroshi Mohri et al. · 2023 · Immunity
  89. Differential neutralizing antibody responses elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in Chile
    2022
  90. Predicting the mutational drivers of future SARS-CoV-2 variants of concern
    M. Cyrus Maher, István Bartha, Steven Weaver, Julia di Iulio, Elena Ferri, Leah B. Soriaga, Florian A. Lempp, Brian Hie, Bryan D. Bryson, Bonnie Berger et al. · 2021 · DSpace@MIT (Massachusetts Institute of Technology)
  91. Nanoparticles and Antiviral Vaccines
    Sen Liu, Meilin Hu, Xiaoqing Liu, Xingyu Liu, Tao Chen, Yiqiang Zhu, Taizhen Liang, Shiqi Xiao, Peiwen Li, Xiancai Ma · 2023 · Vaccines
  92. Protective non-neutralizing SARS-CoV-2 monoclonal antibodies
    Arman Izadi, Pontus Nordenfelt · 2024 · Trends in Immunology
  93. Antibody escape and global spread of SARS-CoV-2 lineage A.27
    Tamara Kaleta, Lisa Kern, Samuel Leandro Hong, Martin Hölzer, Georg Kochs, Julius Beer, Daniel Schnepf, Martin Schwemmle, Nena Bollen, Philipp Kolb et al. · 2022 · Nature Communications
  94. RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants
    Qingtai Liang, Yifeng Wang, Shuyuan Zhang, Jing Sun, Wenbo Sun, Jizhou Li, Yaping Liu, Mingxi Li, Lin Cheng, Yuhang Jiang et al. · 2022 · iScience
  95. Evolution of SARS-CoV-2 in Spain during the First Two Years of the Pandemic: Circulating Variants, Amino Acid Conservation, and Genetic Variability in Structural, Non-Structural, and Accessory Proteins
    Paloma Troyano-Hernáez, Roberto Reinosa, África Holguín · 2022 · International Journal of Molecular Sciences
  96. Alteration of prostaglandin production and agonist responsiveness by n-6 polyunsaturated fatty acids in endometrial cells from late-gestation ewes
    Zhangrui Cheng, Matthew J. Elmes, S E Kirkup, D.R.E. Abayasekara, D. Claire Wathes · 2004 · Journal of Endocrinology
  97. Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies
    Delphine Planas, Timothée Bruel, Isabelle Staropoli, Florence Guivel‐Benhassine, Françoise Porrot, Piet Maes, Ludivine Grzelak, Matthieu Prot, Saïd Mougari, Cyril Planchais et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  98. Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity
    J. Jensen, R. Sankhala, V. Dussupt, Hong-Jun Bai, A. Hajduczki, Kerri G. Lal, William C. Chang, E. Martinez, Caroline E. Peterson, Emily Golub et al. · 2023 · Journal of Virology
  99. Recent progress on the mutations of SARS-CoV-2 spike protein and suggestions for prevention and controlling of the pandemic
    Xue Li, Liying Zhang, Si Emma Chen, Weilong Ji, Chang Li, Linzhu Ren · 2021 · Infection Genetics and Evolution
  100. Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein
    Shiqi Xu, Yifan Wang, Yanxing Wang, Chao Zhang, Hong Qin, Chenjian Gu, Rong Xu, Tingfeng Wang, Yong Ping Yang, Jinkai Zang et al. · 2021 · Emerging Microbes & Infections